Table 1.
Frequency of alterations of TP53, MDM2, and MDMX in relevant hematological neoplasia diseases
| Disease | TP53 mutations | TP53 17p deletion | MDM2 overexpression/trisomy 12 | MDMX overexpression | References |
|---|---|---|---|---|---|
| ALL | 13.5 ± 0.7 (459 pt) | 4.3 ± 1.2 (1731 pt) | 29.3 ± 4.7 (101 pt) | 80 (55 pt) | [147–150] |
| AML | 13.5 ± 2.7 (2934 pt) | 1.5 ± 0.7 (2398 pt) | 49 (189 pt) | 10.7 (140 pt) | [150–156] |
| BL | 17.3 ± 9 (218 pt) | 10 (28 pt) | 13.5 ± 13.4 (109 pt) | 21 (30 pt) | [157–159] |
| CLL | 10.2 ± 1.5 (3703 pt) | 6.8 ± 1.9 (3523 pt) | 13.8 ± 1.8 (3523 pt) | 21 (131 pt) | [76, 150, 160–164] |
| MM | 8.2 ± 5.2 (733 pt) | 10.2 ± 2.7 (954 pt) | 8 (82 pt) | na | [165–170] |
| NHL | 24.4 ± 6.4 (1337 pt) | 25 ± 7.1 (75 pt) | 15.1 ± 17.2 (851 pt) | na | [171–177] |
| WM/LPL | 7 (30 pt) | 8.7 ± 1 (206 pt) | 4 ± 1.4 (214 pt) | na | [178–182] |
The percentages of abnormalities were calculated after compiling cases reported in literature (total number of patients is indicated in bracket) and are reported as mean ± standard deviation
ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, BL Burkitt lymphoma, CLL chronic lymphocytic leukemia, MM multiple myeloma, NHL non-Hodgkin lymphoma, WM/LPL Waldenström macroglobulinemia/lymphoplasmacytic lymphoma, na not available